NEORAL by Novartis is clinical pharmacology cyclosporine is a potent immunosuppressive agent that in animals prolongs survival of allogeneic transplants involving skin, kidney, liver, heart, pancreas, bone marrow, small intestine, and lung. Approved for organ rejection in kidney, liver, heart allogeneic transplants and 2 more indications. First approved in 1997.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
Neoral (cyclosporine) is a potent oral immunosuppressant that selectively inhibits T-lymphocyte activation by blocking interleukin-2 production and lymphokine release. It is indicated for prevention of organ rejection in kidney, liver, and heart transplants, as well as rheumatoid arthritis and severe psoriasis in non-immunocompromised patients. The modified formulation provides superior bioavailability (20-50% greater AUC) compared to the predecessor Sandimmune, with onset of peak concentrations at 1.5-2.0 hours.
As a foundational transplant immunosuppressant approaching loss of exclusivity with minimal current marketing spend ($1M reported), career opportunities focus on managed decline, generic transition planning, and organizational restructuring rather than growth initiatives.
CLINICAL PHARMACOLOGY Cyclosporine is a potent immunosuppressive agent that in animals prolongs survival of allogeneic transplants involving skin, kidney, liver, heart, pancreas, bone marrow, small intestine, and lung. Cyclosporine has been demonstrated to suppress some humoral immunity and to a…
Worked on NEORAL at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy
Tacrolimus/Sirolimus Versus Tacrolimus/Mycophenolate Mofetil (MMF) Versus Neoral/Sirolimus in Adult, Primary Kidney Transplantation
Neoral roles are primarily focused on transition management and margin protection rather than growth; professionals joining this product should expect portfolio consolidation, generic strategy development, and possible organizational realignment. Long-term career trajectory on Neoral is constrained by imminent LOE, making it suitable for late-career specialists or those leveraging transplant expertise to anchor broader immunology portfolios.